Sanofi-Aventis, the makers of the insulin glargine reference product Lantus, has jumped into the biosimilar arena, having received FDA approval on February 14 for an insulin aspart biosimilar. Dubbed Merilog (insulin aspart-szjj), the agent is a rapid-acting insulin whose reference drug is NovoLog. There are two biosimilars to insulin glargine, the long-acting formulation, and this … Continue reading First Insulin Aspart Biosimilar Approved: Sanofi’s Merilog